gefitinib has been researched along with tetracycline in 10 studies
Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (tetracycline) | Trials (tetracycline) | Recent Studies (post-2010) (tetracycline) |
---|---|---|---|---|---|
5,231 | 566 | 2,919 | 21,524 | 977 | 3,656 |
Protein | Taxonomy | gefitinib (IC50) | tetracycline (IC50) |
---|---|---|---|
90-kda heat shock protein beta HSP90 beta, partial | Homo sapiens (human) | 22.4474 | |
heat shock protein HSP 90-alpha isoform 2 | Homo sapiens (human) | 22.4474 | |
tyrosine-protein phosphatase non-receptor type 7 isoform 2 | Homo sapiens (human) | 8.33 | |
30S ribosomal protein S6 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S7 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L15 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L10 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L11 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L7/L12 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L19 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L1 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L20 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L27 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L28 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L29 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L31 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L31 type B | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L32 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L33 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L34 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L35 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L36 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S10 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S11 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S12 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S13 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S16 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S18 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S19 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S20 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S2 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S3 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S4 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S5 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S8 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S9 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L13 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L14 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L16 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L23 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S15 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L17 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L21 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L30 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L6 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S14 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S17 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S1 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L18 | Escherichia coli K-12 | 4.58 | |
Alpha-synuclein | Homo sapiens (human) | 6.06 | |
50S ribosomal protein L2 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L3 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L24 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L4 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L22 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L5 | Escherichia coli K-12 | 4.58 | |
30S ribosomal protein S21 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L25 | Escherichia coli K-12 | 4.58 | |
50S ribosomal protein L36 2 | Escherichia coli K-12 | 4.58 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (40.00) | 29.6817 |
2010's | 6 (60.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Fishkin, PA; Gross, HM; Jatoi, A; Johnson, DB; Kahanic, SP; Loprinzi, CL; Novotny, PJ; Rowland, K; Schaefer, PL; Sloan, JA; Tschetter, LK | 1 |
Atherton, PJ; Burger, KN; Jatoi, A; Loprinzi, CL; Miller, RC; Neben Wittich, MA; Sloan, JA | 1 |
1 review(s) available for gefitinib and tetracycline
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for gefitinib and tetracycline
Article | Year |
---|---|
Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; Drug Evaluation; ErbB Receptors; Exanthema; Female; Gefitinib; Humans; Male; Middle Aged; Placebos; Quality of Life; Quinazolines; Tetracycline | 2008 |
8 other study(ies) available for gefitinib and tetracycline
Article | Year |
---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Using the Skindex-16 and Common Terminology Criteria for Adverse Events to assess rash symptoms: results of a pooled-analysis (N0993).
Topics: Algorithms; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cetuximab; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Humans; Male; Middle Aged; Mometasone Furoate; Neoplasms; Pregnadienediols; Protein Kinase Inhibitors; Protein Synthesis Inhibitors; Quinazolines; Radiodermatitis; Randomized Controlled Trials as Topic; Severity of Illness Index; Sunscreening Agents; Surveys and Questionnaires; Terminology as Topic; Tetracycline | 2012 |